Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer
Brief description of study
The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Selinexor (KPT-330) is a small molecule, oral, first-in-class, potent selective inhibitor of nuclear export (SINE) compound. The study drug selinexor is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-01713
ClinicalTrials.gov Identifier: NCT03555422
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
